6
Participants
Start Date
February 21, 2017
Primary Completion Date
March 23, 2017
Study Completion Date
March 23, 2017
AZD0284
Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
[14C]AZD0284
Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
Research Site, Nottingham
Lead Sponsor
AstraZeneca
INDUSTRY